Literature DB >> 2997089

Primary spinal cord tumors treated with surgery and postoperative irradiation.

D M Garcia.   

Abstract

Between 1954 and 1979, 37 patients with a primary spinal cord tumor received postoperative irradiation after laminectomy. There were 26 intramedullary and 11 tumors of the conus/cauda equina. The 26 intramedullary tumors were divided as follows: 14 astrocytomas, eight ependymomas, three unbiopsied tumors, and one diffuse histiocytic lymphoma. Of the cauda equina tumors, 10 were ependymomas and one was an astrocytoma. Patients were followed until death or for a minimum of 4 years. The 5- and 10-year actuarial survivals for the entire group were 70 and 58%, respectively. Anatomic location of the tumor was the most important predictor of both survival and neurologic function. Patients with tumors of the cauda equina had superior neurologic function and a significantly better survival than those with tumors at other sites. Recurrent tumor was the cause of death in 82% of the patients dead at the time of analysis. Of the patients alive at the conclusion of the study, 10 were completely normal or had only mild neurologic deficit; the remaining 10 patients were severely disabled. Increasing radiation dose correlated with an increase in tumor control and survival. Of those receiving less than 40 Gy, 77% died of recurrent tumor, while 83% of those who received greater than 40 Gy are alive 4.1 to 28.9 years after treatment.

Entities:  

Mesh:

Year:  1985        PMID: 2997089     DOI: 10.1016/0360-3016(85)90274-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  30 in total

Review 1.  Radiation therapy and the management of intramedullary spinal cord tumors.

Authors:  S R Isaacson
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study.

Authors:  Jiang Liu; Minghui Zheng; Wuyang Yang; Sheng-Fu L Lo; Judy Huang
Journal:  J Neurooncol       Date:  2018-05-23       Impact factor: 4.130

Review 3.  Prognostic factors in intramedullary astrocytomas: a literature review.

Authors:  Vladimír Benes; Pavel Barsa; Vladimír Benes; Petr Suchomel
Journal:  Eur Spine J       Date:  2009-06-28       Impact factor: 3.134

4.  Total removal of cervicothoracic intramedullary 160-mm-long spinal cord ependymoma: a rare case report.

Authors:  Alaattin Yurt; Mehmet Selçuki; Ali Rıza Ertürk; Ali Küpelioğlu; Yahya Turan; Muammer Atıcı
Journal:  BMJ Case Rep       Date:  2009-03-06

5.  Radiotherapy of spinal cord gliomas : A retrospective mono-institutional analysis.

Authors:  Stefanie Corradini; Indrawati Hadi; Vinzent Hankel; Lorenz Ertl; Ute Ganswindt; Claus Belka; Maximilian Niyazi
Journal:  Strahlenther Onkol       Date:  2015-10-30       Impact factor: 3.621

6.  Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center.

Authors:  Serap Akyurek; Eric L Chang; Tse-Kuan Yu; Darrin Little; Pamela K Allen; Ian McCutcheon; Anita Mahajan; Moshe H Maor; Shiao Y Woo
Journal:  J Neurooncol       Date:  2006-04-29       Impact factor: 4.130

7.  Conservative surgery and radiotherapy in the treatment of spinal cord astrocytoma.

Authors:  R Jyothirmayi; J Madhavan; M K Nair; B Rajan
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

8.  Recurrence from filum terminale ependymoma 42 years after 'total' removal and radiotherapy.

Authors:  P Celli; L Cervoni; M Salvati; G Cantore
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

9.  Surgical outcome and prognostic factors of spinal intramedullary ependymomas in adults.

Authors:  Ung Kyu Chang; Woo Jin Choe; Sang Kee Chung; Chun Kee Chung; Hyun Jib Kim
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

10.  Ependymoma of the filum terminale: treatment and prognostic factors in a series of 28 cases.

Authors:  P Celli; L Cervoni; G Cantore
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.